Current Report Filing (8-k)
September 12 2016 - 07:47AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant
to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): September 12, 2016
Recro Pharma, Inc.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Pennsylvania
|
|
001-36329
|
|
26-1523233
|
(State or other jurisdiction of
incorporation or organization)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification No.)
|
|
|
|
|
|
490 Lapp Road, Malvern, Pennsylvania
|
|
19355
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrants telephone number, including area code: (484) 395-2470
Not Applicable
(Former
name or former address, if changed since last report)
Check the appropriate box below
if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
On September 12, 2016, Recro Pharma, Inc. (the Company) updated information
reflected in a slide presentation, which is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. Representatives of the Company will use the updated presentation in various meetings with investors from
time to time.
Item 9.01
|
Financial Statements and Exhibits.
|
(d) Exhibits
|
|
|
Exhibit
No.
|
|
Document
|
|
|
99.1
|
|
Investor presentation of Recro Pharma, Inc.
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.
|
|
|
Recro Pharma, Inc.
|
|
|
By:
|
|
/s/ Gerri A. Henwood
|
Name:
|
|
Gerri A. Henwood
|
Title:
|
|
Chief Executive Officer
|
Date: September 12, 2016
EXHIBIT INDEX
|
|
|
Exhibit
No.
|
|
Document
|
|
|
99.1
|
|
Investor presentation of Recro Pharma, Inc.
|
Recro Pharma (NASDAQ:REPH)
Historical Stock Chart
From Feb 2024 to Mar 2024
Recro Pharma (NASDAQ:REPH)
Historical Stock Chart
From Mar 2023 to Mar 2024